Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;20(11):8172-8182.
doi: 10.1002/alz.14219. Epub 2024 Sep 23.

REAL AD-Validation of a realistic screening approach for early Alzheimer's disease

Affiliations

REAL AD-Validation of a realistic screening approach for early Alzheimer's disease

Antoine Leuzy et al. Alzheimers Dement. 2024 Nov.

Abstract

Early diagnosis is crucial to treatment success. This is especially relevant for Alzheimer's disease (AD), with its protracted preclinical phase. Most health care systems do not have the resources to conduct large-scale AD screenings in middle-aged individuals in need of novel AD treatment options and early, accurate diagnosis. Recent developments in blood-based biomarkers and remote cognitive testing offer novel, cost-effective, and scalable methods to detect cognitive and biomarker changes that may indicate early AD. In research cohorts, promising results have been reported, but these modalities have not been validated in population-based settings. The validation of a realistic screening approach for early Alzheimer's disease (REAL AD) study aims to validate the diagnostic and prognostic performance of the combined use of blood-based biomarkers and remote cognitive testing as a screening approach for early AD employing an existing health care infrastructure (the Swedish Västra Götaland Region Primary Healthcare). REAL AD aims to provide a concrete, individualized diagnostic framework, which could significantly improve AD prognosis. HIGHLIGHTS: In Sweden, most Alzheimer's disease (AD) diagnoses are made in primary care, where access to AD biomarkers is almost non-existent. Most health care systems have limited resources for the screening of middle-aged adults for early evidence of AD pathology. Blood-based biomarkers and remote cognitive testing offer novel, cost-effective, and scalable methods for detecting cognitive and biomarker changes that may indicate early AD. The REAL AD study aims to validate the diagnostic and prognostic performance of blood-based biomarkers and remote cognitive testing as a screening approach for early AD in an existing primary health care infrastructure in the Västra Götaland Region in Sweden. Studies such as REAL AD will play a vital role in helping to move the field toward concrete implementation of biomarkers in AD diagnostic workup at all care levels, eventually providing more comprehensive treatments options for the large and growing AD population, and for those at risk.

Keywords: Alzheimer's disease; blood‐based biomarkers; digital biomarker; primary care; screening.

PubMed Disclaimer

Conflict of interest statement

F.H., I.B., F.L., M.D., K.Q., and AM declare no conflicts of interest. A.L. serves as a consultant to Enigma Biomedical Group. S.K. has served on scientific advisory boards, as a speaker, and/or as consultant for Roche, Geras Solutions, Optoceutics, Biogen, and Bioarctic. H.Z. has served on scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche; and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), a part of the GU Ventures Incubator Program (outside submitted work). K.B. has served as a consultant and on advisory boards for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served on data‐monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials, and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai, and Roche Diagnostics; and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), a part of the GU Ventures Incubator Program, outside the work presented in this article. M.S. has served on advisory boards for Roche and Novo Nordisk; received speaker honoraria from Bioarctic, Eisai, Genentech, Novo Nordisk, and Roche; and receives research support (to the institution) from Alzpath, Bioarctic, Novo Nordisk, and Roche. He is a co‐founder of Centile Bioscience and serves as Associate Editor with Alzheimer's Research & Therapy. Author disclosures are available in the supporting information.

Figures

FIGURE 1
FIGURE 1
Overview of the screening study design. Each of the four steps in the screening study encompasses multiple data collection points: baseline, 18‐, 27‐, and 36‐month follow‐up for steps 1 (questionnaires about basic health, demographic, and lifestyle information) and 2 (remote cognitive testing), as well as the optional questionnaires on lifestyle factors, baseline and 18 months for step 3 (blood sampling).
FIGURE 2
FIGURE 2
Map of the Västra Götaland Region (VGR) primary care centers involved in REAL AD. Location of the VGR in Sweden and distribution of public primary care centers taking part in REAL AD across the region.
FIGURE 3
FIGURE 3
Overview of the overall study design including the validation sub‐study. After the baseline screening phase has been completed (top panel), participants will be recruited to the validation sub‐study (bottom panel) and undergo the following examinations at baseline and on a follow‐up occasion 48 months later: Neuropsychological testing, blood and CSF sampling, clinical assessment, structural and functional MRI, as well as tau PET using [18F]RO948.

References

    1. Gustavsson A, Norton N, Fast T, et al. Global estimates on the number of persons across the Alzheimer's disease continuum. Alzheimers Dement. 2023;19:658‐670. - PubMed
    1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS‐ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's Disease. Neurology. 1984;34:939‐944. - PubMed
    1. Jack CR Jr, Bennett DA, Blennow K, et al. NIA‐AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535‐562. - PMC - PubMed
    1. Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: alzheimer's Association Workgroup. Alzheimers Dement. 2024;20:5143‐5169. - PMC - PubMed
    1. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS‐ADRDA criteria. Lancet Neurol. 2007;6:734‐746. - PubMed

Publication types

Grants and funding